MedMira and AHD Achieve First Sales Win in Indonesia as a Result of South East Asia Market Expansion



    HALIFAX, April 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, and US-based sales and marketing partner American Health
Diagnostics LLC (AHD), announced today that their South East Asia market
expansion initiatives have resulted in product sales in Indonesia. As
announced in August 2008, MedMira and AHD are working together to break in to
this developing market and sell at least one million rapid HIV tests in the
South East Asia region over the next year.
    Local distributors Lauw Management USA and PT Sehat Selaras Sejahtera,
along with MedMira and AHD pursued and received regulatory approval in
Indonesia for MedMira's MiraWell Rapid HIV Test (MiraWell HIV). In addition to
regulatory approval, the sales and marketing registrations required to sell
the product in this market has also been completed.
    "We have converted our Southeast Asia market expansion into concrete
sales opportunities in Indonesia. Working with our partners, AHD, Lauw
Management USA, and PT Sehat Selaras Sejahtera, we were able to move through
the evaluation and regulatory process smoothly in order to realize our first
sales in the region," said Hermes Chan, president and CEO, MedMira Inc. "This
is the first in a series of initiatives included in our market development
plan for the region. Working with our strategic partners in South East Asia we
will sell our competitively priced, quality diagnostics to other countries in
the region."
    AHD, Lauw Management USA, and PT Sehat Selaras Sejahtera will use the
first shipment of MiraWell HIV to target both private and public sector
customers. With a comprehensive sales and marketing campaign slated to begin
in May, follow-on orders are anticipated in the coming months.
    "We are very excited about bringing this product to customers in
Indonesia," said Brad Adams, Executive Vice President of AHD. "We are well on
our way to establishing MiraWell HIV as a brand known for quality and
performance and fully developing the sales opportunities that exist in
Indonesia for this product."

    About American Health Diagnostics

    American Health Diagnostics brings innovations to life through a
proprietary market readiness process and proven distribution management
network. The AHD market readiness and distribution management system has been
utilized to introduce MedMira's Reveal(R) Rapid HIV-1 Antibody Test, the
market's fastest FDA approved HIV test, and ThyroTec's ThyroTest(TM), the
first ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening
device. www.ahpartners.com

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Andrea Young, Corporate Communications,
MedMira, (902) 450-1588, ayoung@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890